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Abstract. 
 
Myogenic differentiation is a highly orches-
trated, multistep process that is coordinately regulated 
by growth factors and cell adhesion. We show here that 
integrin-linked kinase (ILK), an intracellular integrin– 
and PINCH-binding serine/threonine protein kinase, is 
an important regulator of myogenic differentiation. 
ILK is abundantly expressed in C2C12 myoblasts, both 
before and after induction of terminal myogenic differ-
entiation. However, a noticeable amount of ILK in the 
Triton X-100–soluble cellular fractions is signiﬁcantly 
reduced during terminal myogenic differentiation, sug-
gesting that ILK is involved in cellular control of myo-
genic differentiation. To further investigate this, we 
have overexpressed the wild-type and mutant forms of 
ILK in C2C12 myoblasts. Overexpression of ILK in the 
myoblasts inhibited the expression of myogenic pro-
teins (myogenin, MyoD, and myosin heavy chain) and 
the subsequent formation of multinucleated myotubes. 
Furthermore, mutations that eliminate either the 
PINCH-binding or the kinase activity of ILK abolished 
its ability to inhibit myogenic protein expression and al-
lowed myotube formation. Although overexpression of 
the ILK mutants is permissive for the initiation of ter-
minal myogenic differentiation, the myotubes derived 
from myoblasts overexpressing the ILK mutants fre-
quently exhibited an abnormal morphology (giant myo-
tubes containing clustered nuclei), suggesting that ILK 
functions not only in the initial decision making pro-
cess, but also in later stages (fusion or maintaining myo-
tube integrity) of myogenic differentiation. Addition-
ally, we show that overexpression of ILK, but not that 
of the PINCH-binding defective or the kinase-deﬁcient 
ILK mutants, prevents inactivation of MAP kinase, 
which is obligatory for the initiation of myogenic differ-
entiation. Finally, inhibition of MAP kinase activation 
reversed the ILK-induced suppression of myogenic 
protein expression. Thus, ILK likely inﬂuences the ini-
tial decision making process of myogenic differentia-
tion by regulation of MAP kinase activation. 
Key words: integrin • PINCH • MAP kinase • myo-
genin • myotubes
 
Introduction
 
Terminal myogenic differentiation is a highly orches-
trated, multistep process that is controlled by environmen-
tal cues including growth factors and the extracellular ma-
trix (McDonald et al., 1995; Sastry and Horwitz, 1996;
Wewer and Engvall, 1996; Durbeej et al., 1998; Gullberg et
al., 1998; Burkin and Kaufman, 1999). For example, it has
been well described that differentiation of myoblasts
plated on appropriate extracellular matrix proteins (e.g.,
collagens) into multinucleated myotubes can be induced
by depriving the cells of growth factors (Weintraub, 1993;
Lassar et al., 1994; Olson and Klein, 1994; Andres and
Walsh, 1996). During this process, the activity of MAP ki-
nase is downregulated and expression of myogenic tran-
scription factors such as myogenin is upregulated, fol-
lowed by expression of other muscle-specific proteins such
as myosin heavy chain (MHC)
 
1
 
 and subsequent formation
of multinucleated myotubes (Lassar et al., 1994; Andres
and Walsh, 1996; Bennett and Tonks, 1997).
Extensive studies over the last one and a half decades
have demonstrated crucial roles of cell adhesion receptors,
including integrins, in the regulation of terminal myogenic
differentiation (McDonald et al., 1995; Sastry and Hor-
witz, 1996; Gullberg et al., 1998; Burkin and Kaufman,
1999). In genetic model systems such as 
 
Drosophila
 
 and
 
Address correspondence to Chuanyue Wu, Department of Pathology,
University of Pittsburgh, 717B Scaife Hall, 3550 Terrace Street, Pitts-
burgh, PA 15261. Tel.: (412) 648-2350. Fax: (509) 561-4062. E-mail:
carywu@imap.pitt.edu
 
1
 
Abbreviations used in this paper:
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Caenorhabditis elegans
 
, it has been well documented that
integrins are involved in sarcomere formation and stabili-
zation or muscle cell attachment (Volk et al., 1990; Gett-
ner et al., 1995; Martin-Bermudo and Brown, 1996; Bloor
and Brown, 1998; Bunch et al., 1998; Gullberg et al., 1998;
Prokop et al., 1998). In vertebrates, a number of integrins
are expressed in muscle cells, and the expression level,
subtype, and activation state of the integrins are precisely
regulated during myogenesis (Boettiger et al., 1995; Sastry
and Horwitz, 1996; Gullberg et al., 1998; Burkin and Kauf-
man, 1999). Antibody ligation of specific 
 
b
 
1 integrins in-
hibits vertebrate myoblast differentiation (Menko and
Boettiger, 1987; Rosen et al., 1992). Furthermore, gene
transfer experiments have demonstrated that myoblast
differentiation and proliferation are regulated by 
 
b
 
1 inte-
grins (Sastry et al., 1996) and this regulation is achieved
through the 
 
b
 
1 integrin cytoplasmic domain (Sastry et al.,
1999). Studies using chimeric transgenic mice that were 
 
a
 
5
integrin 
 
2
 
/
 
2
 
: 
 
1
 
/
 
1
 
 showed that the 
 
a
 
5 
 
2
 
/
 
2
 
 cells were able
to contribute to skeletal muscle, but the myofibers were
unstable, resulting in a form of muscular dystrophy (Ta-
verna et al., 1998). Similar results showing a mild muscular
dystrophy were obtained with a targeted deletion of the 
 
a
 
7
integrin chain (Mayer et al., 1997), and mutations in the
human integrin 
 
a
 
7 gene lead to a congenital myopathy
(Hayashi et al., 1998). Thus, integrins function in terminal
myogenic differentiation by participating in both the ini-
tial decision making process and the later morphogenic
processes such as cell fusion and maintaining the integrity
of myotubes.
Integrin-linked kinase (ILK) is a focal adhesion serine/
threonine protein kinase that interacts with 
 
b
 
1 integrins
through the COOH-terminal domain (Hannigan et al.,
1996; Dedhar et al., 1999) and PINCH, an adaptor protein
comprising five LIM domains, through the NH
 
2
 
-terminal
ankyrin (ANK) repeat domain (Tu et al., 1999; Wu, 1999).
The ILK-binding site has been mapped to the COOH-ter-
minal zinc finger, which is located within the first LIM do-
main of PINCH (Li et al., 1999a; Wu, 1999). The ILK–
PINCH interaction is required for proper subcellular
localization of ILK (Li et al., 1999a; Wu, 1999). Further-
more, it may also connect ILK with components of the
growth factor and small GTPase signaling pathways via
other PINCH-binding proteins such as Nck-2 (Tu et al.,
1998; Wu, 1999). Recent biochemical and functional stud-
ies have indicated that ILK serves as a mediator in inte-
grin-mediated signal transduction (Hannigan et al., 1996;
Radeva et al., 1997; Delcommenne et al., 1998; Novak et
al., 1998; Wu et al., 1998; Troussard et al., 1999; Tu et al.,
1999; Wu, 1999). In this study, we have investigated the
roles and potential mechanisms of ILK in cellular control
of terminal myogenic differentiation.
 
Materials and Methods
 
Antibodies
 
Mouse monoclonal anti-ILK antibody 65.1 was generated as previously
described (Li et al., 1999a). Mouse monoclonal anti-FLAG antibody M5
was from Eastman Kodak Co. Mouse monoclonal antimyogenin F5D and
anti–MyoD 5.8A were from PharMingen. Hybridoma for monoclonal
anti–myosin heavy chain (MHC) antibody MF20 was obtained from the
Developmental Studies Hybridoma Bank. Rabbit polyclonal anti-FAK
 
antibody C-20 was purchased from Santa Cruz Biotechnology, Inc. An-
tiphosphotyrosine antibody RC20:HRPO was purchased from Transduc-
tion Laboratories. Rabbit polyclonal anti-p44/42 MAPK and anti–phos-
pho-p44/42 MAPK (Thr202/Tyr204) antibodies were purchased from New
England BioLabs. HRP-conjugated goat anti–mouse IgG and goat anti–
rabbit IgG were purchased from Jackson ImmunoResearch Laboratories.
 
Cell Culture and Myogenic Differentiation
 
Mouse C2C12 myoblasts (American Type Culture Collection) were main-
tained at subconfluent densities in growth medium (GM) consisting of
DME (Life Technologies) supplemented with 10% FBS (Sigma Chemical
Co.). To induce terminal myogenic differentiation, cells were seeded into
collagen I–coated plates (Becton Dickinson), and were shifted to differen-
tiation medium (DM) consisting of DME supplemented with 2% horse se-
rum (Sigma Chemical Co.) when the cells reached 70–80% confluence.
 
Construction and Transfection of Wild-type and 
Mutant Forms of FLAG-tagged ILK
 
To create NH
 
2
 
-terminal FLAG epitope-tagged proteins, cDNAs encoding
the mouse wild-type ILK (residues 1–452) and the PINCH-binding defec-
tive ANK1 deletion mutant (residues 66–452, referred to as 
 
D
 
ANK1), re-
spectively, were cloned into a mammalian expression vector pFLAG-
CMV-2 (Eastman Kodak Co.) as described previously (Li et al., 1999a). A
cDNA encoding the human kinase–deficient ILK mutant (referred to as
KD) containing a single mutation (Glu
 
359
 
 
 
®
 
 Lys) was PCR amplified from
the recombinant plasmid GH31R (Novak et al., 1998; Wu et al., 1998) and
cloned into pFLAG-CMV-2 using EcoRI-SalI sites.
To generate stable transfectants, C2C12 cells were cotransfected with
pFLAG-CMV-2 vectors containing ILK, 
 
D
 
ANK1, or KD cDNA, or
pFLAG-CMV-2 vector lacking the ILK sequence as a control, and
pcDNA3 (Invitrogen) carrying a neomycin-resistant marker at a ratio of
10:1, using the LipofectAMINE PLUS reagent (Life Technologies).
C2C12 cells expressing the FLAG-tagged wild-type and mutant forms of
ILK were selected with 1 mg/ml of G418 (Life Technologies) and cloned
as described previously (Li et al., 1999b). A total of five FLAG-ILK–
expressing clones (C27, E1.3, F6.2, F31, and F41), three FLAG-
 
D
 
ANK1–
expressing clones (G2, G24, and G43), and three FLAG-KD–expressing
clones (B38, E20, and H15) were isolated independently. The cells were
maintained in culture medium containing 200 
 
m
 
g/ml of G418.
 
Immunoblotting
 
Cells were washed twice with PBS and lysed in ice-cold RIPA extraction
buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% NP-40, 1% Triton
X-100, 0.25% sodium deoxycholate, 2 mM EDTA, and 2 mM EGTA)
containing protease inhibitors 4-(2-aminoethyl)-benzenesulfonyl fluoride
(0.2 mM), 10 
 
m
 
g/ml aprotinin, 1 
 
m
 
g/ml pepstatin, and 5 
 
m
 
g/ml leupeptin
(Sastry et al., 1999) unless otherwise specified. The cell lysates were clari-
fied by centrifugation at 10,000 
 
g
 
 for 15 min. Protein concentration of the
clarified lysates was determined using bicinchoninic acid (BCA) protein
assay reagents (Pierce Chemical Co.). Proteins (5–15 
 
m
 
g) were resolved by
SDS-PAGE and transferred onto Immobilon-P membranes (Millipore).
The membranes were blocked with TBST buffer (20 mM Tris-HCl, pH
7.6, 150 mM NaCl, 0.1% Tween 20) containing 5% nonfat dry milk and in-
cubated with primary antibodies (0.5–1 
 
m
 
g/ml) as specified in each experi-
ment. After three washes with TBST, the membranes were incubated with
appropriate secondary antibodies (1:10,000 dilution) and washed, and the
bound antibodies were detected with SuperSignal chemiluminescent sub-
strate (Pierce Chemical Co.).
For immunoblotting analysis of phospho-p44/42 MAPK, cells cultured
in GM or DM for 3 h were lysed in the RIPA buffer containing protease
inhibitors (as described above) and phosphatase inhibitors (30 mM so-
dium pyrophosphate, 100 mM NaF, 2 mM sodium orthovanadate). An
equal amount (8 
 
m
 
g/lane) of the cell lysates was separated on 8% SDS-
PAGE gels. After blotting, the membranes were blocked with 2% BSA in
TBST. Active MAPK was detected with an anti–phospho(Thr202/
Tyr204)-p44/42 MAPK antibody that specifically recognizes the active
forms of MAPK (New England BioLabs). Duplicate membranes were an-
alyzed for the total MAPK with an anti-p44/42 MAPK polyclonal anti-
body (New England BioLabs). The membranes were reprobed with an
anti-FAK polyclonal antibody (C-20) to confirm equal loading of pro-
teins.
For immunoblotting analysis of ILK, parental C2C12 cells were cul- 
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tured in GM or induced to differentiate in DM for 6 d and harvested. Half
of the cells was lysed in PBS, pH 7.4, containing 1% Triton X-100 and pro-
tease inhibitors 4-(2-aminoethyl)-benzenesulfonyl fluoride (0.2 mM), 10
 
m
 
g/ml aprotinin, 1 
 
m
 
g/ml pepstatin, and 5 
 
m
 
g/ml leupeptin. The other half
was lysed in PBS, pH 7.4, containing 1% SDS and the protease inhibitors.
An equal amount (10 
 
m
 
g/lane) of the cell lysates was separated on 10%
SDS-PAGE gels, and ILK was detected by immunoblotting with a mono-
clonal anti-ILK antibody 65.1 (Li et al., 1999a).
For myogenin and MyoD immunoblotting, cells cultured in GM or in-
duced to differentiate in DM for 4 d were lysed in lysis buffer (20 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 1% SDS, 2 mM EDTA, 2 mM EGTA)
containing protease inhibitors as described above. An equal amount (15
 
m
 
g/lane) of the cell lysates was separated on 10% SDS-PAGE gels. The
membranes were first immunoblotted with an antimyogenin mAb F5D or
anti-MyoD mAb 5.8A, and were reprobed with anti-MHC mAb F20, anti-
FLAG mAb M5, or anti-FAK polyclonal antibody C-20 as specified in
each experiment.
 
Immunoprecipitation
 
Cells cultured in GM or in DM for 4 d were lysed in the RIPA buffer con-
taining protease inhibitors and phosphatase inhibitors as described above.
The cell lysates (300 
 
m
 
g) were mixed with 10 
 
m
 
l of polyclonal anti-FAK
antibody C-20 (2 
 
m
 
g) in a final volume of 500 
 
m
 
l. The samples were incu-
bated at 4
 
8
 
C for 2 h with continuous agitation. 10 
 
m
 
l of UltraLink immobi-
lized protein G (Pierce Chemical Co.) was added and incubated at 4
 
8
 
C for
an additional 2 h. The beads were pelleted gently and washed four times
with RIPA buffer. The precipitated proteins were released from the beads
by boiling in 60 
 
m
 
l of SDS-PAGE sample buffer for 5 min. Equal volumes
of the samples were loaded onto SDS-PAGE. Total FAK protein and the
tyrosine-phosphorylated FAK were detected by immunoblotting with
anti-FAK antibody C-20 and antiphosphotyrosine antibody RC20:HRPO
(Transduction Laboratories), respectively.
 
Inhibition of p44/42 MAPK Activity
 
The activation of MAPK in C2C12 cells was inhibited by treatment of the
cells with specific MEK inhibitor PD98059 (New England BioLabs) based
on a previously described method (Sastry et al., 1999). In brief, ILK-over-
expressing and parental C2C12 cells were cultured in GM or DM in the
presence or absence of 25 
 
m
 
M PD98059 for a period of time, as specified
in each experiment, and lysed with the RIPA buffer. MAPK activation
and myogenin expression were analyzed by immunoblotting with anti–
phospho(Thr202/Tyr204)-p44/42 MAPK antibody and antimyogenin anti-
body F5D, respectively, as described above.
 
Nuclear Staining
 
Cells were cultured in GM or DM for 4 d in a 24-well tissue culture plate.
The cells were rinsed with PBS, fixed with 4% paraformaldehyde solution
in PBS for 20 min at room temperature, and incubated with permeabiliza-
tion solution (0.1% Triton X-100 and 0.1% sodium citrate) for 2 min at
4
 
8
 
C. After rinsing with PBS, the cells were incubated with 20 
 
m
 
g/ml of
Hoechst 33258 (Sigma Chemical Co.) in PBS for 5 min and observed un-
der a fluorescence microscope.
 
Results
 
ILK Regulates Terminal Myogenic Differentiation
 
To begin to investigate the roles of ILK in regulation of
terminal myogenic differentiation, we analyzed the cellu-
lar levels of ILK in C2C12 myoblasts before and after in-
duction of myogenic differentiation by immunoblotting
with a monoclonal anti-ILK antibody. Abundant ILK was
detected in Triton X-100 lysates of C2C12 myoblasts cul-
tured in growth medium (Fig. 1, lane 1). Additional slower
migrating bands, which could represent either detergent-
resistant ILK-containing complexes or other ILK-related
proteins (Li et al., 1999a), were also detected in the C2C12
lysates (Fig. 1). After switching to differentiation medium
for 6 d, the amount of ILK in the Triton X-100 lysates of
C2C12 myoblasts was noticeably reduced (Fig. 1, compare
lane 2 with lane 1). The reduction of the ILK level in the
Triton X-100 lysates accompanying terminal myogenic dif-
ferentiation could result from a decrease of overall cellular
ILK or, alternatively, from a more selective reduction of
ILK in the Triton X-100–soluble fractions including mem-
brane and cytosolic fractions. To test this, we extracted the
total cellular proteins from the C2C12 cells with SDS. Im-
munoblotting analyses of the SDS extracts indicated that
the overall cellular level of ILK was not decreased after in-
duction of terminal myogenic differentiation (Fig. 1, lanes
3 and 4). Taken together, these results indicate that the
amount of ILK in the Triton X-100–soluble subcellular
fractions, but not the overall cellular level of ILK, was de-
creased accompanying terminal myogenic differentiation.
The correlation between the downregulation of ILK
level in the Triton X-100–soluble fractions and the termi-
nal myogenic differentiation suggests that ILK is likely in-
volved in the regulation of myogenic differentiation. To
investigate this, we overexpressed an epitope (FLAG)-
tagged ILK in C2C12 myoblasts. C2C12 myoblasts were
transfected with an expression vector containing the full-
length ILK coding sequence under the CMV promoter
(pFLAG-ILK). The FLAG-ILK transfectants were se-
lected with G418 and cloned as described previously (Li et
al., 1999b). A total of five FLAG-ILK–expressing C2C12
clones (C27, E1.3, F6.2, F31, and F41) were independently
obtained. The expression of FLAG-ILK in the C2C12 cells
before and after the induction of myogenic differentiation
was confirmed by immunoblotting (Fig. 2 a, lanes 6–15).
No FLAG-ILK was detected in the parental C2C12 cells
(Fig. 2 a, lanes 1–5) or the vector-only control transfec-
tants (Fig. 2 a, lanes 16–20).
One of the critical events at the initiation of terminal
myogenic differentiation is induction of myogenin, which
is a member of the MyoD family of skeletal muscle–spe-
cific, basic Helix-Loop-Helix transcription factors (Lassar
et al., 1994). As expected, myogenin was not detected in
C2C12 cells grown in growth medium (Fig. 2 b, lanes 1, 6,
11, and 16). Myogenin expression was induced in the pa-
rental C2C12 cells and the vector-only control transfec-
tants after they were shifted to differentiation medium
(Fig. 2 b, lanes 1–5 and 16–20). By contrast, the induction
of myogenin expression was almost completely inhibited
in C2C12 cells overexpressing FLAG-ILK (Fig. 2 b, lanes
Figure 1. The amount of
ILK in Triton X-100–soluble
fractions is reduced during
terminal myogenic differenti-
ation. Mouse C2C12 myo-
blasts were cultured in
growth medium (GM) and
induced to differentiate by
switching to the differentia-
tion medium (DM). The cells
were extracted with lysis
buffers containing 1% Triton
X-100 or 1% SDS as described in Materials and Methods. ILK in
the Triton X-100 (lanes 1 and 2) or SDS (lanes 3 and 4) extracts
were analyzed by immunoblotting with a monoclonal anti-ILK
antibody 65.1. 
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6–15). In additional experiments, we have found that over-
expression of FLAG-ILK also significantly reduced the
expression of MyoD, another member of the MyoD family
of basic Helix-Loop-Helix transcription factors (data not
shown). Overexpression of FLAG-ILK did not affect
FAK expression under either the growth or differentiation
condition (Fig. 2 c), suggesting that ILK selectively regu-
lates the expression of the muscle-specific transcription
factors.
We next analyzed the effect of ILK overexpression on
MHC, another marker for terminal myogenic differentia-
tion. Abundant myosin heavy chain was expressed by the
parental C2C12 cells and the vector-only transfectants af-
ter they were shifted to the differentiation medium (Fig. 3
a, lanes 2 and 4). By marked contrast, no MHC was de-
tected in cells overexpressing FLAG-ILK, either before or
after induction of differentiation (Fig. 3 a, lanes 5–8).
Equal protein loading was confirmed by probing the same
membrane with a polyclonal anti-FAK antibody (Fig. 3 b).
Thus, overexpression of ILK inhibits the expression of
MHC as well as that of myogenin and MyoD, indicating
that ILK plays a crucial role in the regulation of myogenic
protein expression.
After induction of myogenic protein expression, C2C12
cells undergo extensive cell fusion, resulting in the forma-
tion of multinucleated myotubes (Andres and Walsh,
1996). As expected, abundant multinucleated myotubes
were detected in both the parental C2C12 cells and the
vector-only control transfectants 4 d after induction of dif-
ferentiation (Fig. 4, b and d). In marked contrast, cells that
overexpress FLAG-ILK failed to form multinucleated myo-
tubes under identical experimental conditions (Fig. 4, f
and h). Thus, consistent with an inhibitory role of ILK in
myogenic protein expression, overexpression of FLAG-
ILK in C2C12 myoblasts suppresses the formation of
multinucleated myotubes.
 
The Kinase Activity of ILK Is Required for Suppression 
of Myogenic Differentiation
 
ILK contains four ankyrin repeats at the NH
 
2
 
 terminus
and a protein kinase catalytic domain at the COOH termi-
nus (Hannigan et al., 1996; Li et al., 1997; Dedhar et al.,
1999; Wu, 1999). To test whether the ILK kinase catalytic
activity is involved in suppression of myogenic differentia-
tion, we expressed a FLAG-tagged kinase-deficient (KD)
ILK point mutant (Novak et al., 1998; Wu et al., 1998), in
which the highly conserved Glu
 
359
 
 within the ILK catalytic
domain was substituted with lysine, in C2C12 cells. The
expression of FLAG-KD in the transfectants before and
after induction of myogenic differentiation was confirmed
by immunoblotting (Fig. 5 a, lanes 5–8). Overexpression of
the kinase-deficient ILK mutant, unlike that of the wild-
type ILK (Figs. 5, b and c, lane 4), did not inhibit the ex-
pression of myogenin (Fig. 5 b, lanes 6 and 8), MyoD (data
not shown), or MHC (Fig. 5 c, lanes 6 and 8). Equal pro-
tein loading was confirmed by probing the same mem-
branes with a polyclonal anti-FAK antibody (Fig. 5 d).
Thus, ablation of the kinase activity relieves the inhibition
on the expression of myogenin, MyoD, and MHC, indicat-
ing that ILK inhibits myogenic protein expression, at least
in part, through its catalytic activity.
 
Role of the PINCH-binding Activity of ILK in the 
Suppression of Myogenic Differentiation
 
The NH
 
2
 
-terminal ankyrin repeat domain of ILK mediates
interaction with PINCH (Tu et al., 1999), an adaptor pro-
tein comprising five LIM domains (Rearden, 1994; Wu,
1999). To assess whether PINCH binding plays a role
in suppression of myogenic differentiation, we expressed
a FLAG-tagged PINCH-binding defective ILK mutant
(
 
D
 
ANK1; Li et al., 1999a), in which the first ankyrin repeat
is deleted, in C2C12 cells. Expression of FLAG-
 
D
 
ANK1
(Fig. 6 a, lanes 9–12) in the transfectants, but not in the
Figure 2. Effect of ILK on myogenin expression. Lysates (15 mg
protein/lane) from cells cultured in growth medium (day 0) or in
differentiation medium (DM) for 1, 2, 3, or 4 d were immunoblot-
ted with anti-FLAG mAb M5 (a), antimyogenin mAb F5D (b),
and anti-FAK polyclonal antibody C-20 (c). (lanes 1–5) Parental
C2C12 cells; (lanes 6–10) FLAG-ILK–expressing clone E1.3;
(lanes 11–15) FLAG-ILK–expressing clone C27; (lanes 16–20)
vector-only control transfectants. Similar results were obtained
with all five independently isolated FLAG-ILK–expressing
clones.
Figure 3. Effect of ILK on
myosin heavy chain expres-
sion. Lysates (15 mg protein/
lane) from cells cultured in
GM (day 0) or DM for 4 d
were immunoblotted with
anti-MHC mAb F20 (a) and
anti-FAK antibody C-20 (b).
(lanes 1 and 2) Parental
C2C12 cells; (lanes 3 and 4)
the vector-only control trans-
fectants; (lanes 5 and 6)
FLAG-ILK–overexpressing
clone E1.3; (lanes 7 and 8)
FLAG-ILK–overexpressing
clone C27. Similar results were obtained with all five indepen-
dently isolated FLAG-ILK–expressing clones. 
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parental C2C12 or the vector-only control (Fig. 6 a, lanes
1–4), before and after induction of differentiation was con-
firmed by immunoblotting. After induction of myogenic
differentiation, the C2C12 cells that express the PINCH-
binding defective ILK mutant (Fig. 6, lanes 10 and 12), like
the parental C2C12 cells (Fig. 6, lane 2) or the vector-only
transfectants (Fig. 6, lane 4), expressed myogenin (Fig. 6
b) and MHC (Fig. 6 c). In parallel control experiments, as
expected, the induction of myogenin and myosin heavy
chain was inhibited in cells expressing FLAG-ILK (Fig. 6,
b and c, lane 8) but not in those expressing the kinase-defi-
cient ILK mutant (Fig. 6, b and c, lane 6). Analysis of
MyoD expression revealed that overexpression of the
PINCH-binding defective ILK mutant, unlike that of the
wild-type ILK, did not decrease MyoD expression (data
not shown). Taken together, these results suggest that in
addition to the kinase catalytic activity, the PINCH-bind-
ing activity is most likely also required for the suppression
of myogenic protein expression.
 
Expression of the PINCH-binding Defective or
Kinase-deficient ILK Mutants Resulted in the 
Formation of Myotubes with Abnormal Morphology
 
Extracellular matrix and growth factors not only control
the expression of myogenic transcription factors and other
Figure 4. Effect of ILK on myotube formation.
Parental C2C12 cells (a and b), the vector-only
control transfectants (c and d), the FLAG-ILK–
overexpressing clones C27 (e and f), and E1.3 (g
and h) were grown in GM (left) and switched to
DM for 4 d (right). Abundant myotubes were
observed in C2C12 (b) and the vector control
(d), but not in FLAG-ILK–expressing clones
C27 (f) and E1.3 (h), after induction of differen-
tiation. Similar results were obtained with all five
independently isolated FLAG-ILK–expressing
clones. Bar, 100 mm. 
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myogenic proteins, but also influence cell fusion and orga-
nization of myotubes. Previous studies have suggested that
cell adhesion receptors including integrins are involved in
cell fusion and organization of myotubes (Menko and
Boettiger, 1987; Volk et al., 1990; Rosen et al., 1992; Boet-
tiger et al., 1995; Mayer et al., 1997; Durbeej et al., 1998;
Gullberg et al., 1998; Taverna et al., 1998; Burkin and
Kaufman, 1999; Montanaro et al., 1999; Tachibana and
Hemler, 1999). To assess whether ILK plays a role in the
myogenic morphogenesis, we analyzed myotube forma-
tion by C2C12 cells overexpressing the kinase-deficient
and PINCH-binding defective ILK mutants. The results
showed that C2C12 cells overexpressing the kinase-defi-
cient mutant (Fig. 7, c and d) or the PINCH-binding defec-
tive mutant (Fig. 7, e and f), unlike those overexpressing
FLAG-ILK (Fig. 7, g and h), were able to form multinu-
cleated myotubes after induction of differentiation. How-
ever, the myotubes derived from the cells overexpressing
the mutant forms of ILK frequently exhibited an abnor-
mal morphology (Fig. 7, c–f). In contrast to myotubes de-
rived from the parental C2C12 (Fig. 7 a) or the vector-only
transfectants (Fig. 7 b), in which nuclei were well aligned
along the myotubes, we have observed in cells overex-
pressing the ILK mutants many giant myotubes in which
nuclei were clustered (Fig. 7, c–f). These results suggest
that ILK, in addition to influencing the initial decision
making process, may also play a role in the later stages
(cell fusion or organization of myotubes) of terminal myo-
genic differentiation.
 
ILK Influences Initiation of Terminal Myogenic 
Differentiation through Regulation of p44/42 MAP 
Kinase (Erk1 and Erk2) Activation
 
Integrins control the terminal myogenic differentiation, at
least in part, by regulation of MAP kinase activation (Sas-
try et al., 1999). Consistent with previous studies (Bennett
and Tonks, 1997), the amounts of active forms of p44/42
Figure 5. Overexpression of the kinase-deficient ILK mutant
fails to inhibit myogenic protein expression. Parental C2C12 cells
(lanes 1 and 2), FLAG-ILK–expressing clone F6.2 (lanes 3 and
4), and FLAG-KD–expressing clones B38 (lanes 5 and 6) and
E20 (lanes 7 and 8) were cultured in GM (day 0) or DM for 4 d.
Cell lysates (15 mg protein/lane) were immunoblotted with anti-
FLAG mAb M5 (a), antimyogenin mAb F5D (b), anti-MHC
mAb MF20 (c), and anti-FAK antibody C-20 (d). Similar results
were obtained with all three independently isolated FLAG-KD–
overexpressing clones.
Figure 6. Overexpression of the PINCH-binding defective ILK
mutant fails to inhibit myogenic protein expression. Parental
C2C12 cells (lanes 1 and 2), the vector control (lanes 3 and 4),
FLAG-KD–expressing clone B38 (lanes 5 and 6), FLAG-ILK–
expressing clone E1.3 (lanes 7 and 8), and FLAG-DANK1–
expressing clones G24 (lanes 9 and 10) and G43 (lanes 11 and 12)
were cultured in GM (day 0) or DM for 4 d. Cell lysates (15 mg
protein/lane) were immunoblotted with anti-FLAG mAb M5 (a),
antimyogenin mAb F5D (b), anti-MHC mAb MF20 (c), and anti-
FAK antibody C-20 (d). Similar results were obtained with all
three independently isolated FLAG-DANK1–overexpressing
clones. 
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MAP kinases (Erk1 and Erk2) in the parental C2C12 cells
(Fig. 8 a, lanes 1 and 2) and the vector-only control cells
(Fig. 8 a, lanes 7 and 8) were decreased upon induction
of terminal myogenic differentiation. By contrast, the
amount of active forms of p44/42 MAP kinases (Erk1 and
Erk2) in C2C12 cells overexpressing the wild-type ILK re-
mained high after shifting to differentiation medium (Fig.
8 a, lanes 3–6). Probing the same samples with an anti-p44/
42 MAP kinase antibody showed that the total protein
level of the p44/42 MAP kinases was not altered by over-
expression of ILK or induction of differentiation (Fig. 8 b,
lanes 1–8). Equal protein loading was confirmed by immu-
noblotting with an anti-FAK antibody (Fig. 8 c, lanes 1–8).
Because the downregulation of MAP kinase activity is re-
quired for myoblasts to initiate terminal myogenic differ-
entiation (Bennett and Tonks, 1997; Sastry et al., 1999),
these results suggest that ILK suppresses myogenic differ-
entiation, at least in part, by preventing inactivation of
p44/42 MAP kinases.
To further analyze the mechanism by which ILK regu-
lates myogenic differentiation, we examined the effects of
overexpression of the kinase-deficient or the PINCH-
binding defective ILK mutants on activation of p44/42
MAP kinases. In contrast to C2C12 cells overexpressing
the wild-type ILK (Fig. 8 a, lanes 3–6), the amounts of the
active forms of p44/42 MAP kinases in C2C12 cells over-
expressing the ILK mutants (Fig. 8 a, lanes 9–16) were
downregulated after shifting to differentiation medium.
Figure 7. Effect of the kinase-deficient and the
PINCH-binding defective ILK mutants on myo-
genic morphogenesis. Parental C2C12 cells (a),
the vector-only control transfectants (b), FLAG-
KD–expressing clones B38 (c) and E20 (d),
FLAG-DANK1–expressing clones G24 (e) and
G43 (f), and FLAG-ILK–expressing clones C27
(g) and F41 (h) were cultured in DM for 4 d,
fixed, and stained with Hoechst 33258. Multinu-
cleated myotubes were detected in C2C12 (a),
vector control (b), and the ILK mutant–express-
ing cells (c–f) but not the FLAG-ILK–expressing
cells (g and h). Giant myotubes with clustered
nuclei were evident in FLAG-KD– and FLAG-
DANK1–expressing cells (c–f). Similar results
were obtained with all independently isolated
FLAG-KD–overexpressing and FLAG-DANK1–
overexpressing clones. Bar, 250 mm. 
The Journal of Cell Biology, Volume 150, 2000 868
 
The total protein level of the p44/42 MAP kinases was not
altered by overexpression of the ILK mutants (Fig. 8 b,
lanes 9–16). Equal protein loading was further confirmed
by immunoblotting with an anti-FAK antibody (Fig. 8 c,
lanes 9–16). These results indicate that ablation of the ki-
nase activity or the PINCH-binding activity of ILK elimi-
nated its ability to regulate MAP kinase activation. Be-
cause neither the kinase-deficient mutant nor the PINCH
defective mutant inhibits terminal myogenic differentia-
tion, these results provide additional evidence suggesting
that p44/42 MAP kinases serve as downstream effectors of
ILK in the regulation of terminal myogenic differentia-
tion. In contrast to the major difference in MAP kinase ac-
tivation, FAK activation, as indicated by the tyrosine
phosphorylation level of FAK, in the ILK-overexpressing
C2C12 cells, parental C2C12 cells and the vector-only
transfectants, did not differ under either growth (Fig. 9 a)
or differentiation (Fig. 9 b) condition, suggesting that ILK
likely regulates MAP kinase activation via a pathway inde-
pendent of FAK activation. This result is consistent with
previous findings showing that the FAK tyrosine phosphor-
ylation level is not altered during the 
 
a
 
5
 
b
 
1 integrin–medi-
ated suppression of myogenic differentiation (Sastry et al.,
1999).
We reasoned that if ILK indeed suppresses myogenic
differentiation through sustaining MAP kinase activation,
 
inactivation of MAP kinase should reverse the ILK-
induced suppression of terminal myogenic differentiation.
To test this, we treated the cells with PD98059, a MEK in-
hibitor that specifically inhibits MAP kinase activation
(Alessi et al., 1995). As expected, p44/42 MAP kinases were
inactivated in parental C2C12 cells after mitogen depriva-
tion, either in the absence or presence of the MEK inhibi-
tor (Fig. 10 a, lanes 1–3). In ILK-overexpressing C2C12
cells, whereas p44/42 MAP kinases remained active after
mitogen deprivation in the absence of the MEK inhibitor
(Fig. 10 a, lanes 5, 8, and 11), the amounts of active forms
of p44/42 MAP kinases were significantly reduced in the
presence of the MEK inhibitor (Fig. 10 a, lanes 6, 9, and
12). Thus, activation of p44/42 MAP kinases that were in-
duced by ILK overexpression was effectively inhibited by
the specific MEK inhibitor PD98059, indicating that ILK
activates p44/42 MAP kinases through MEK. In further
supporting a key role of MAP kinase in the ILK-induced
suppression of myogenic differentiation, inhibition of MAP
kinase reversed the ILK-induced suppression of myogenin
(Fig. 10 b, lanes 6, 9, and 12) and myosin heavy chain (data
not shown) expression. In control experiments, myogenin
was readily detected in parental C2C12 cells after mitogen
deprivation, either in the absence or presence of the MEK
inhibitor (Fig. 10 b, lanes 2 and 3). We conclude from
these results that ILK influences the initial decision mak-
ing process of myogenic differentiation by regulation of
MAP kinase activation.
Figure 8. Regulation of p44/42 MAP kinase activation by ILK.
Parental C2C12 cells (lanes 1 and 2), FLAG-ILK–overexpressing
clones F6.2 (lanes 3 and 4) and E1.3 (lanes 5 and 6), the vector-
only control transfectants (lanes 7 and 8), FLAG-KD–overex-
pressing clones E20 (lanes 9 and 10) and B38 (lanes 11 and 12),
and FLAG-DANK1–overexpressing clones G43 (lanes 13 and
14) and G24 (lanes 15 and 16) were cultured in GM (0 h) or
shifted to DM for 3 h. Cell lysates (8 mg protein/lane) were immu-
noblotted with an anti–phospho(Thr202/Tyr204)-p44/42 MAPK
antibody that specifically recognizes the active forms of MAPK
(a), an anti-p44/42 MAPK that recognizes total p44/42 MAPK pro-
teins (b) and an anti-FAK antibody (c), respectively.
Figure 9. Tyrosine phosphorylation of FAK is not affected by
ILK. Parental C2C12 cells, the vector control transfectants, and
FLAG-ILK–expressing clones E1.3, C27, and F41 were cultured
in GM (a) or in DM (b) for 4 d. FAK was immunoprecipitated
from cell lysates with a rabbit polyclonal anti-FAK antibody C-20
or irrelevant rabbit IgG as indicated in the figure. Total FAK
protein (lanes 1–6) and the tyrosine-phosphorylated FAK (lanes
7–12) in the immunoprecipitates were detected by immunoblot-
ting with anti-FAK antibody C-20 and an HRP-conjugated an-
tiphosphotyrosine antibody RC20:HRPO, respectively. 
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Discussion
 
How myoblastic cells control terminal myogenic differen-
tiation is a fascinating and clinically important question.
Although it has been well established that growth factors
and extracellular matrix proteins, through interactions
with their cell-surface receptors, provide crucial signals
controlling terminal myogenic differentiation (McDonald
et al., 1995; Sastry and Horwitz, 1996; Wewer and Engvall,
1996; Durbeej et al., 1998; Gullberg et al., 1998; Burkin
and Kaufman, 1999), the intracellular events transducing
the signals are not completely understood. In this study,
we have identified ILK as an important regulator in the
initial decision making process of myogenic differentia-
tion. A correlation between downregulation of the ILK
level in the Triton X-100–soluble fractions and terminal
myogenic differentiation was observed. In further experi-
mental studies, we found that overexpression of ILK effec-
tively inhibits the expression of myogenic transcription
factors and suppresses the subsequent myotube formation.
The inhibition of myogenic differentiation requires both
the PINCH-binding and the kinase activities of ILK, sug-
gesting that the relative amount, subcellular localization,
and the kinase activity of ILK are crucial elements in the
cellular regulation of terminal myogenic differentiation.
The finding that ILK functions in the initial decision
making process of terminal myogenic differentiation is
consistent with recent studies by Sastry et al. (1999) who
have demonstrated that overexpression of the 
 
b
 
1 integrin
cytoplasmic domain inhibits terminal myogenic differenti-
ation. ILK was initially identified based on its interaction
with the 
 
b
 
1 integrin cytoplasmic domain (Hannigan et al.,
1996). ILK is present in cell–matrix adhesion sites (Li et
al., 1999a). Furthermore, the kinase activity of ILK can be
activated by integrin-mediated cell adhesion to fibronectin
(Delcommenne et al., 1998). In a recent study, we have
found that MIBP, a muscle-specific 
 
b
 
1 integrin binding
protein, is critically involved in the regulation of myogenic
differentiation (Li et al., 1999b). Because both ILK (Han-
nigan et al., 1996) and MIBP (Li et al., 1999b) interact with
the 
 
b
 
1 cytoplasmic domain, it is attractive to propose that
ILK works in concert with MIBP and other integrin-proxi-
mal proteins such as FAK and paxillin (Sastry et al., 1999)
in transducing signals from 
 
b
 
1 integrins to downstream
targets leading to the suppression of terminal myogenic
differentiation.
A key downstream target of integrin-mediated regula-
tion of terminal myogenic differentiation is MAP kinase
(Sastry et al., 1999). Overexpression of the 
 
b
 
1 integrin cy-
toplasmic domain enhances MAP kinase activation, which
maintains the myoblasts in a proliferative, undifferenti-
ated state (Sastry et al., 1999). Inhibition of MAP kinase
activation, on the other hand, relieves the integrin-medi-
ated suppression of myogenic differentiation (Sastry et al.,
1999). Thus, inactivation of MAP kinases is an essential
event in integrin-mediated regulation of myoblast cell cy-
cle withdrawal and initiation of terminal myogenic differ-
entiation (Sastry et al., 1999). In this study, we have dem-
onstrated that overexpression of ILK, but not that of the
PINCH-binding defective or the kinase-deficient ILK mu-
tant, resulted in a sustained activation of MAP kinases
(Erk1 and Erk2). Furthermore, inhibition of MAP kinase
activation reverses the ILK-induced suppression of myo-
genic differentiation. These results provide strong evi-
dence for the notion that ILK is an important component
of the integrin signaling pathway that regulates MAP ki-
nase activation and, ultimately, the decision of prolifera-
tion versus differentiation. Because MAP kinase activa-
tion is critically involved in cell cycle progression through
the G1 phase (Bottazzi et al., 1999; Roovers et al., 1999), a
process that is corporately regulated by growth factors and
integrins (Assoian, 1997; Schwartz, 1997; Howe et al., 1998;
Giancotti and Ruoslahti, 1999), the finding that ILK en-
hances MAP kinase activation is also consistent with re-
cent observations that overexpression of ILK in epithelial
cells promotes anchorage-independent cell cycle progres-
sion (Radeva et al., 1997) and tumor formation (Wu et al.,
1998).
In addition to demonstrating a prominent role in the ini-
tial decision making process of terminal myogenic differ-
entiation, our results suggest that ILK may also play a role
in the later stages of myogenic differentiation, namely
modulation of cell fusion or maintaining the integrity of
myotubes. Overexpression of the PINCH-binding defec-
tive or the kinase-deficient ILK mutants, which is permis-
sive for the initiation of myogenic differentiation, resulted
in the formation of myotubes with altered morphology (gi-
ant myotubes containing clustered nuclei). ILK is a multi-
domain protein with several distinct biochemical activities
including integrin-binding, PINCH-binding, and catalysis
of serine/threonine phosphorylation (Dedhar et al., 1999;
Wu, 1999). Thus, ILK mutants, in which one of the activi-
ties (e.g., PINCH-binding or kinase activity) is ablated,
could function as dominant negative inhibitors of endoge-
nous ILK. Indeed, a dominant negative inhibitory effect of
the kinase-deficient ILK mutant in ILK signaling has been
observed in previous studies (Delcommenne et al., 1998;
Troussard et al., 1999). A role of ILK in the modulation of
Figure 10. Inactivation of MAPK reverses the ILK-induced sup-
pression of myogenin expression. Parental C2C12 cells (lanes
1–3) and FLAG-ILK–expressing clones C27 (lanes 4–6), F6.2
(lanes 7–9), and E1.3 (lanes 10–12) were grown in GM or in DM
in the absence (2) or presence (1) of the specific MEK inhibitor
PD98059 as indicated in the figure. Cells were harvested 24 h (a)
or 4 d (b) after PD98059 treatment. The active forms of MAPK
and myogenin were detected by immunoblotting with an anti–
phospho(Thr202/Tyr204)-p44/42 MAPK antibody (a) and an an-
timyogenin antibody F5D (b), respectively. 
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myogenic morphogenesis is further supported by previous
studies showing that alterations in the expression or func-
tions of 
 
b
 
1 integrins, to which ILK binds (Hannigan et al.,
1996), resulted in abnormal muscle structure. For exam-
ple, dystrophic muscles with giant muscle fibers or in-
creased numbers of nuclei per fiber with altered position
and size have been observed in 
 
a
 
5 integrin (
 
11
 
;
 
22
 
) chi-
meric mice (Taverna et al., 1998) and mice lacking 
 
a
 
7 inte-
grin (Mayer et al., 1997). Treatment of myoblasts with an
antibody that alters 
 
a
 
5
 
b
 
1 integrin function also results in
the formation of myotubes with an altered morphology
(e.g., myotubes with clustered nuclei; Boettiger et al.,
1995). The similar effects of ILK and the 
 
b
 
1 integrins on
myogenic morphogenesis strongly suggest that ILK func-
tions in this process through, at least in part, modulation of
integrin signaling. Recent studies in 
 
C. elegans
 
 have pro-
vided strong genetic evidence for a critical role of ILK and
its binding partner PINCH in integrin functions during
muscle development. Deficiency in 
 
b
 
-integrin/
 
pat-3 results
in a specific developmental arrest phenotype termed Pat
(paralyzed and arrested elongation at the twofold stage),
which is caused by a dysfunction of body wall muscles
(Gettner et al., 1995). The loss of expression of either ILK/
pat-4 (Mackinnon, A.C., and B. Williams, personal com-
munication) or PINCH/unc97 (Hobert et al., 1999) causes
a similar body wall muscle–defective Pat phenotype. The
dual functions of ILK in myogenesis suggest that ILK may
play a crucial role in the regulation of normal muscle re-
generation as well as pathological conditions, such as mus-
cular dystrophies or other myopathies.
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